文献速递先天性心脏病外科心外重症与机械循环支持

Barth综合征心脏移植后结局良好

Favorable outcomes after heart transplantation in Barth syndrome.
PubMed 文献 · J Heart Lung Transplant · 2021-07-10

该研究跨三个登记库识别Barth综合征(BTHS)心脏移植受者,并按1:4匹配非BTHS扩张型心肌病男性受者。BTHS受者移植后生存率与对照组无差异,急性排斥反应更少,感染和恶性肿瘤无差异。结论认为有指征时BTHS患者心脏移植是合适的。

要点

  • BTHS心脏移植后生存率与非BTHS扩张型心肌病受者相当。
  • BTHS受者急性排斥反应自由度更高,感染和恶性肿瘤无差异。
  • 有指征时BTHS患者心脏移植是合适的。

核心结论

  • BTHS患者心脏移植后生存率与非BTHS扩张型心肌病受者无差异,且急性排斥反应更少,感染和恶性肿瘤无差异,有指征时移植是合适的。

研究设计与样本

  • 跨3个登记库识别BTHS心脏移植受者,并按1:4匹配非BTHS男性扩张型心肌病心脏移植受者,分析人口学和生存数据,部分队列分析感染、恶性肿瘤、移植物血管病变和急性排斥。

主要发现

  • 移植时机械循环支持常见:心室辅助装置29%,体外膜肺氧合5%。
  • 中位随访4.5年(IQR 2.7-9.1),BTHS受者生存与非BTHS受者无差异(HR 0.91,95% CI 0.40-2.12,p=0.85)。
  • 有PHTS数据的BTHS受者(n=28)感染自由度(HR 0.64,0.34-1.22;p=0.18)、恶性肿瘤(HR 0.22,0.02-2.01,p=0.18)和移植物血管病变(HR 0.58,0.16-2.1,p=0.41)无差异。
  • 急性排斥自由度更高(HR 0.39,0.17-0.86,p=0.02),尽管诱导治疗(61 vs 73%,p=0.20)、30天激素(75 vs 62%,p=0.27)和1年双/三联免疫抑制(80 vs 84%,p=0.55)使用相似。

临床怎么用

  • 对于有心脏移植指征的BTHS患者,移植是合适的治疗选择,术后急性排斥风险可能较低。

局限性

  • 感染、恶性肿瘤、移植物血管病变和急性排斥分析仅限有PHTS数据的28名BTHS受者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Barth Syndrome (BTHS) is a rare, X-linked disease characterized by cardioskeletal myopathy and neutropenia. Comparative outcomes after heart transplantation have not been reported. METHODS: We identified BTHS recipients across 3 registries (Pediatric Heart Transplant Study Registry [PHTS], Barth Syndrome Research Registry and Repository, and Scientific Registry of Transplant Recipient-Pediatric Health Information System) and matched them 1:4 to non-BTHS, male heart transplant (HT) recipients listed with dilated cardiomyopathy in PHTS. Demographics and survival data were analyzed for all recipients, whereas post-HT infection, malignancy, allograft vasculopathy, and acute rejection were only available for analysis for individuals with PHTS data. RESULTS: Forty-seven BTHS individuals with 51 listings and 43 HTs (including 2 re-transplants) were identified. Age at primary HT was 1.7 years (IQR: 0.6-4.5). Mechanical circulatory support at HT was common (ventricular assist device 29%, extracorporeal membrane oxygenation 5%). Over a median follow-up of 4.5 years (IQR 2.7-9.1), survival for BTHS HT recipients was no different than non-BTHS HT recipients (HR 0.91, 95% CI 0.40-2.12, p = 0.85). Among those with PHTS data (n = 28), BTHS HT recipients showed no difference in freedom from infection (HR 0.64, 0.34-1.22; p = 0.18), malignancy (HR 0.22, 0.02-2.01, p = 0.18), and allograft vasculopathy (HR 0.58, 0.16-2.1, p = 0.41). Freedom from acute rejection (HR 0.39, 0.17-0.86, p = 0.02) was greater for BTHS HT recipients despite similar use of induction (61 vs 73%, p = 0.20), steroids at 30-days (75 vs 62%, p = 0.27), and dual/triple drug immunosuppression at 1-year (80 vs 84%, p = 0.55). CONCLUSIONS: In this largest cohort yet reported, individuals with BTHS have equivalent survival with less acute rejection and no difference in infection or malignancy after HT. When indicated, HT for individuals with BTHS is appropriate.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Li Y, Godown J, Taylor CL, et al. Favorable outcomes after heart transplantation in Barth syndrome. J Heart Lung Transplant. 2021. PMID: 34330606. doi:10.1016/j.healun.2021.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。